This is a group of inherited conditions where tumors grow in several different glands that make hormones. These glands include the thyroid, parathyroid, and adrenal glands. It can cause various types of tumors.
Every report comes from a Lived member, sent anonymously.
Have you had Parathyroidectomy for Multiple Endocrine Neoplasia?
Multiple endocrine neoplasia (MEN) is a group of inherited conditions that cause tumors to grow in the body's hormone-making (endocrine) glands, often in two or more of them over a person's life. Most of these tumors are benign, meaning not cancer, but they can make too much hormone and upset calcium balance, blood sugar, stomach acid or blood pressure. Some can become cancerous, which is why MEN calls for lifelong attention even when a person feels well. There are three main types, each caused by a different gene and each with its own pattern. MEN1 mainly affects the parathyroid glands in the neck (which control blood calcium), the pituitary gland at the base of the brain (which directs many other glands), and the pancreas and upper small intestine. MEN2 almost always leads to medullary thyroid cancer, a cancer of the thyroid's calcitonin-making C cells, and can also cause pheochromocytoma, an adrenal gland tumor that releases adrenaline-like hormones and can push blood pressure dangerously high. MEN2A, the common form of MEN2, can also involve the parathyroid glands. The rarer MEN2B causes thyroid cancer very early in childhood, along with small bumps on the lips and tongue and a tall, thin build. MEN4 is rare and resembles MEN1. MEN1 and MEN2 each affect roughly 1 in 30,000 to 35,000 people.
Each type of MEN is caused by a change (variant) in a single gene: MEN1 for type 1, RET for type 2 and CDKN1B for type 4. In MEN1 and MEN4, the gene normally acts as a brake on cell growth, and losing it lets cells in endocrine tissue multiply. In MEN2, the RET variant does the opposite, switching on a growth signal that should be off. Diet, lifestyle and environment do not cause MEN. MEN is inherited in an autosomal dominant pattern, which means one altered copy of the gene is enough. A parent with MEN has a 1 in 2 chance of passing it to each child, and sons and daughters are equally affected. In about 1 in 10 people with MEN1 the variant is new, appearing for the first time in that person, so a family history without MEN does not rule it out. Carriers are very likely to develop tumors over their lifetime. In MEN1, which glands are affected and when can differ even among relatives with the same variant. In MEN2, the specific RET variant strongly predicts how early and how aggressively thyroid cancer appears, which is why the exact genetic result guides care.
MEN is usually identified in one of three ways: a person develops tumors in two or more of the typical glands, a person has one typical tumor and a close relative with MEN, or genetic testing finds a disease-causing variant, even before any symptoms. Certain findings raise suspicion on their own, such as overactive parathyroid glands in a person's teens or 20s (in the general population this usually appears in the 50s), medullary thyroid cancer at a young age or in both sides of the thyroid, or a pheochromocytoma. Genetic testing, usually on a blood or saliva sample, looks for the variant. Once a family's variant is known, parents, siblings and children are offered testing; in MEN2 families children are tested early because decisions about thyroid surgery begin in childhood. A negative test for the known family variant means that person does not have MEN, is unlikely to develop its tumors and cannot pass it on. Up to 1 in 4 people with clear signs of MEN1 have no variant found, and the diagnosis then rests on the tumors themselves. Blood tests show which glands are overactive. Common examples are calcium and parathyroid hormone for the parathyroid glands, prolactin and other pituitary hormones, gastrin (a hormone that drives stomach acid), calcitonin (a marker made by thyroid C cells that rises with medullary thyroid cancer) and metanephrines, breakdown products of adrenaline that reveal a pheochromocytoma. MRI, CT, ultrasound and specialized scans that highlight neuroendocrine tumors (hormone-making tumors such as those in the pancreas) show where tumors are and how large they have grown.
There is no treatment that reverses the underlying gene change, so care focuses on finding tumors early and treating each one when it matters. For carriers, that means a schedule of blood tests and imaging that continues for life, tailored to the type and, in MEN2, to the specific RET variant. Small tumors that make no excess hormone and are not growing are often watched rather than treated. In MEN1, overactive parathyroid glands are usually treated with surgery to remove the affected glands, often several of them because all four tend to be involved over time; medicines can control calcium when surgery is not possible. Tumors of the pancreas and duodenum are managed with acid-reducing medicines when a gastrinoma (a gastrin-making tumor) causes ulcers, and with surgery when a tumor makes troublesome hormones, grows or looks likely to spread. One such tumor is an insulinoma, which makes too much insulin and can drive blood sugar dangerously low; it is usually removed surgically. Pituitary tumors are treated with medicine, surgery or both, and radiation is used less often. In MEN2, the central treatment is removing the thyroid before cancer develops or spreads. The timing depends on the RET variant: within the first year of life for children with the usual MEN2B variant, around age 5 or earlier for other high-risk variants, and guided by calcitonin levels and neck ultrasounds for moderate-risk variants. Before thyroid surgery, and during pregnancy, a pheochromocytoma has to be ruled out with blood or urine tests, because an undetected one can set off a dangerous surge in blood pressure during an operation or in labor. A pheochromocytoma that is found is usually removed with keyhole (laparoscopic) surgery after medicines are given to block the effects of its hormones. If medullary thyroid cancer has spread and needs drug treatment, targeted pills that block the overactive RET signal can shrink tumors and keep them in check. Selpercatinib (Retevmo) is approved for advanced RET-mutant medullary thyroid cancer in adults and children 2 and older. These medicines control the cancer rather than cure it and require regular monitoring for side effects.
MEN is lifelong, but with regular screening and timely treatment most people with MEN1 live long and productive lives, and MEN2 thyroid cancer found and removed early has a very good outlook. Day to day, MEN usually means a steady rhythm of appointments, blood tests and scans, often coordinated by an endocrinologist working with surgeons, gastroenterologists and genetic counselors. Tumors often come back, or new ones appear, years after surgery, so follow-up continues even when someone feels well. Surgery can leave lasting hormone needs. Anyone whose thyroid is removed takes thyroid hormone every day for life. Removing more than three parathyroid glands can leave calcium too low, which is treated with calcium and vitamin D. Removing both adrenal glands means lifelong steroid hormone replacement and a risk of adrenal crisis, a dangerous shortage of stress hormones during illness or injury, which is one reason surgeons try to spare adrenal tissue when they can. People in this situation are taught how to take extra steroid doses during illness and when to use an emergency injection. In MEN1, the tumors with the most effect on long-term outlook are cancers of the pancreas and duodenum, which is why those organs get close attention. In MEN2, thyroid cancer that has already spread is harder to cure and is often managed over many years. Because MEN runs in families, a diagnosis often affects parents, siblings and children too. Genetic counseling helps families decide who to test and when, think through testing children, and plan pregnancies, including options for testing a pregnancy or an embryo.
Ask about genetic counseling and testing if a close relative has MEN or a known MEN gene variant, or if you have had overactive parathyroid glands at a young age, more than one endocrine tumor, medullary thyroid cancer or a pheochromocytoma. If you already have MEN, keep to your screening schedule rather than waiting for symptoms, since many tumors cause none early on. Contact your care team about new symptoms that suggest a hormone problem. Kidney stones, bone pain, or ongoing thirst and tiredness can be signs of high calcium from the parathyroid glands. Burning stomach pain, reflux or persistent diarrhea can be signs of excess stomach acid from a gastrinoma. A lump in the neck can come from the thyroid, and new headaches or changes in vision can mean a pituitary tumor is pressing on nearby nerves. Episodes of a pounding heartbeat, sweating and headache can signal a pheochromocytoma. Tell any surgeon or obstetrician that you have MEN2 before an operation or delivery. In MEN1, spells of shakiness, sweating or hunger that ease after eating can be low blood sugar from an insulinoma and should be checked promptly. Call 911 if someone with low blood sugar becomes confused, passes out or has a seizure.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Multiple Endocrine Neoplasia is like, what's helped you, or ask the community a question.